| Page 1418 | Kisaco Research
 

Diwaker Daver

Assistant Professor of Medicine
Assistant Professor of Medicine University of Pittsburgh

Bio: Dr. Davar is a translational oncologist whose research interests lies in translational cancer immunotherapy and early-phase clinical trials. He has been instrumental in the development of first-in-human studies evaluating novel agents targeting TIGIT, GITR, TIM-3, CTLA-3 and other immune checkpoints. Based on emerging data implicating intestinal dysbiosis in mediating non-response to PD-1 blockade, he developed a protocol evaluating fecal microbiota transplant in combination with PD-1 blockade to treat PD-1 non-responders.

Diwaker Daver

Assistant Professor of Medicine
Assistant Professor of Medicine University of Pittsburgh

Diwaker Daver

Assistant Professor of Medicine
Assistant Professor of Medicine University of Pittsburgh

Bio: Dr. Davar is a translational oncologist whose research interests lies in translational cancer immunotherapy and early-phase clinical trials. He has been instrumental in the development of first-in-human studies evaluating novel agents targeting TIGIT, GITR, TIM-3, CTLA-3 and other immune checkpoints. Based on emerging data implicating intestinal dysbiosis in mediating non-response to PD-1 blockade, he developed a protocol evaluating fecal microbiota transplant in combination with PD-1 blockade to treat PD-1 non-responders. This first-in-human study was selected for funding by Merck to support the clinical costs. Results demonstrating that microbiome modulation reversed primary resistance to anti-PD-1 and augmented anti-tumor immunity were recently published in Science.

 

Nikole Kimes, Ph.D.

Founder and Chief Executive Officer
Siolta Therapeutics

 

Nikole Kimes, Ph.D.

Founder and Chief Executive Officer
Siolta Therapeutics

Nikole Kimes, Ph.D.

Founder and Chief Executive Officer
Siolta Therapeutics

 

 

Peter Marks

Director
Center for Biologics Evaluation and Research, FDA

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development.  He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.

Peter Marks

Director
Center for Biologics Evaluation and Research, FDA

Peter Marks

Director
Center for Biologics Evaluation and Research, FDA

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development.  He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.

 

Frederik Madsen

CEO
Cirqle Biomedical

Frederik is co-founder and CEO at Cirqle Biomedical, a women's health company developing OUI®.

 

OUI is a first-in-class non-hormonal contraceptive that works by topically reinforcing the natural barrier properties of cervical mucus to prevent sperm cells from reaching and fertilising the egg. The novel mechanism of action has been demonstrated to provide breakthrough efficacy in pre-clinical animal studies. 

 

Frederik Madsen

CEO
Cirqle Biomedical

Frederik Madsen

CEO
Cirqle Biomedical

Frederik is co-founder and CEO at Cirqle Biomedical, a women's health company developing OUI®.

 

OUI is a first-in-class non-hormonal contraceptive that works by topically reinforcing the natural barrier properties of cervical mucus to prevent sperm cells from reaching and fertilising the egg. The novel mechanism of action has been demonstrated to provide breakthrough efficacy in pre-clinical animal studies. 

 

Cirqle has been awarded the Index Award, dubbed the Nobel Prize of the design world, and has been featured by amongst others Forbes, CNN and Wired Magazine for its pioneering work.

 

Frederik brings unique experience on the opportunities of applying human-centred innovation in women's health. He holds a MSc in Management of Innovation and Business Development from Copenhagen Business School.

 

Emily Zhen

Health Venture Capital Investor
New Enterprise Associates

Emily Zhen

Health Venture Capital Investor
New Enterprise Associates

Emily Zhen

Health Venture Capital Investor
New Enterprise Associates
 

Elena Gambon

VP Business Development
First Stop Health

Elena Gambon

VP Business Development
First Stop Health

Elena Gambon

VP Business Development
First Stop Health
 

Dr. Patrick Carroll

Chief Medical Officer
Hims & Hers

Dr. Patrick Carroll

Chief Medical Officer
Hims & Hers

Dr. Patrick Carroll

Chief Medical Officer
Hims & Hers
 

Deena Shakir

Partner
LUX Capital

Deena Shakir

Partner
LUX Capital

Deena Shakir

Partner
LUX Capital
 

Akash Bashi

CEO
YourChoiceTherapeutics

Akash Bashi

CEO
YourChoiceTherapeutics

Akash Bashi

CEO
YourChoiceTherapeutics
 

Moshe Mishali

Co-founder and CEO
Deep AI

Moshe Mishali

Co-founder and CEO
Deep AI

Moshe Mishali

Co-founder and CEO
Deep AI